when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Fierce Biotech·6h ago·1 min read

AbCellera becomes latest biotech to abandon dream of developing OX40 drug

Nov 10, 2026·read at Fierce Biotech ↗

AbCellera has become the latest drug developer to abandon its attempts to crack the OX40 code.

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗

sharex / twitter linkedin

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

7h agoCoherus shrinks headcount 30% to narrow focus of cancer comboFierce Biotech
20h agoMerck’s MASH hopeful efinopegdutide wins in mid-stage studyFierce Biotech
1d agoZura scraps hidradenitis suppurativa program after phase 2 miss, sinking stockFierce Biotech
1d agoJ&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depressionFierce Biotech
1d agoSanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from ChinaFierce Biotech